A subset of flavaglines inhibits KRAS nanoclustering and activation

A subset of flavaglines inhibits KRAS nanoclustering and activation

The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loa...

Full description

Bibliographic Details
Main Authors: Yurugi, Hajime, Zhuang, Yinyin, Siddiqui, Farid A., Liang, Hong, Rosigkeit, Sebastian, Zeng, Yongpeng, Abou-Hamdan, Hussein, Bockamp, Ernesto, Zhou, Yong, Abankwa, Daniel, Zhao, Wenting, Désaubry, Laurent, Rajalingam, Krishnaraj
Other Authors: School of Chemical and Biomedical Engineering
Format: Journal Article
Language:English
Published: 2021
Subjects:
Engineering::Bioengineering
KRAS
Phospholipid
Online Access:https://hdl.handle.net/10356/149025

Similar Items

Similar Items